CHARLES BLACKBURN: Open Payments
NPI 1821449679 · SAINT CLAIR, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,647 in 98 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $151 · 2025 $1,647
Food & beverage: $1,647
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $524 |
| AstraZeneca Pharmaceuticals LP | 6 | $185 |
| Novo Nordisk Inc | 13 | $182 |
| Amgen Inc. | 15 | $135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $103 |
| SANOFI-AVENTIS U.S. LLC | 3 | $93 |
| Lilly USA, LLC | 4 | $89 |
| Exact Sciences Corporation | 3 | $58 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
Products named: VRAYLAR, AIRSUPRA, QULIPTA, UBRELVY, OTEZLA, CAPLYTA, TZIELD, MOUNJARO.
Industry payments across MO — which companies pay providers there.
